Eli Lilly and Company & Nvidia

Eli Lilly and Company: Eli Lilly and Company>>> advanced after positive trial results for its next-generation obesity drug, retatrutide, which showed benefits beyond weight loss.

Nvidia: Nvidia's stronger-than-expected quarterly report and revenue forecast, driven by demand for its AI chips, significantly boosted market sentiment and led to a rally in technology stocks across Asia and Wall Street. Despite a slight dip in after-hours trading, its performance was a key driver of the overall market gains.

Eli Lilly and Company: Eli Lilly's stock jumped after a committee of the European Medicines Agency recommended one of its medicines for approval, boosting its market performance.

Nvidia: Fell 3.7% in one session, heaviest weight on S&P 500; lost over $300 billion in market cap in a single day.

Eli Lilly and Company: Eli Lilly is partnering with Abridge to streamline care across the health sector.

Nvidia: Nvidia is partnering with Abridge to streamline care across the health sector.

Eli Lilly and Company: Eli Lilly and Company is one of the healthcare leaders whose contracts were added to Phemex's TradFi ecosystem, making its assets available for 24/7 trading to Phemex users.

Nvidia: Nvidia is an existing high-demand asset already available on Phemex, and its inclusion in the expanded TradFi offering reinforces its accessibility for users.

Eli Lilly and Company: Eli Lilly and Company is mentioned as one of the companies that SpaceX's valuation will surpass, emphasizing the magnitude of SpaceX's market entry.

Nvidia: Nvidia is mentioned as the world's most valuable public company, providing a benchmark for SpaceX's market valuation.